Motility News

A novel upper esophageal sphincter assist device successfully treated reflux-associated laryngeal symptoms in a pragmatic exploratory clinical trial, according to research published in Clinical Gastroenterology and Hepatology.

Synergy Pharmaceuticals announced the FDA has approved Trulance for the treatment of constipation-predominant irritable bowel syndrome in adults.

Patients with obesity who underwent personalized, multidisciplinary health education and monitoring over a 6-month period saw improvement in their GERD symptoms, as well as their quality of life and weight, according to a study published in The American Journal of Gastroenterology’s “Putting Patients First” special issue.

Children who received a combination of interferential electrical stimulation and pelvic floor muscle exercises as treatment for functional constipation saw significant improvement of their symptoms, according to the results of a randomized controlled trial published in The American Journal of Gastroenterology.

Amitriptyline, a tricyclic antidepressant, improved functional dyspepsia symptoms better than the selective serotonin reuptake inhibitor escitalopram, and neither slowed gastric emptying, according to the results of an international multicenter randomized controlled trial.

The FDA has accepted a new drug application for Baremsis for the management of post-operative nausea and vomiting, according to the manufacturer.

Individuals who regularly used proton pump inhibitors showed no increased risk for stroke in a new study published in Gastroenterology.

Tenapanor showed positive results in a safety extension study, which the manufacturer Ardelyx said will support a new drug application along with two successful phase 3 trials for constipation-predominant irritable bowel syndrome, according to a press release.

Elderly patients with gastroesophageal reflux disease showed a higher risk for malignancies of the upper aerodigestive tract in a recent case-control study.

EndoGastric Solutions announced the launch of its new device, EsophyX Z+, which offers expanded endoscope compatibility and supports the transoral incisionless fundoplication 2.0 procedure to reconstruct the gastroesophageal valve and restore its function as a reflux barrier.